Overview of all our clinical studies and available
biobanks
Normal control pediatric populations
Leipzig school children project:
= representative normal
populations
n~3000 total; n~1200 for
consented DNA analysis
LIFE Child Health:
= longitudinal childhood population
including detailed anthropometric and metabolic
phenotyping
n>3500 total (ongoing)
More information
Obese pediatric populations
Leipzig Obesity Childhood Cohort:
incl. detailed
phenotyping and oGTT's n>2200 (incl. follow-ups
n>500)
Leipzig Atherobesity Childhood Cohort:
obese children
n=100 and lean children n=70
incl.
detailed metabolic and cardiovascular phenotyping and MRI scans as well as
follow-up data
LIFE Child Obesity:
= longitudinal childhood population
incl. detailed metabolic phenotyping
n>340 participants
in total (n>680 visits, incl. follow-ups)
More information
Special populations
Intervention in obese children:
= inpatients, 6 week
exercise intervention
n=62 incl. detailed phenotyping
Leipzig Circadian Rhythm Cohort:
= young
healthy lean and obese adults incl. frequent serum sampling over 30
h
n=59 incl. detailed metabolic phenotyping
Adipose tissue pediatric biobank:
= adipose tissue
samples from lean and obese children incl. consented DNA analysis
n=467 total currently (incl. 395 samples),
ongoing study
Pediatric populations for genotyping
n~1000 incl. MetaboChip data:
cohorts contributed to
MAGIC and EGG consortia, collaborations and publications
- Metabolic traits
(Scott, Nature genet Epub) collaboration
- intrauterine
growth (Hokoshi, Nature Epub) collaboration
-
available for own analyses
n>2000 incl. targeted (candidate) genetic analyses and
GWAS replication:
- FTO (Dina, Nat genet
2007) collaboration
- GWAS (Meyre, Nat
genet 2009; Scherag, PLoS genet 2010)
collaboration
- TCF7L2 (Körner, JCEM 2007)
- Metabolic
traits (Windholz, PLoS One 2011)
- GPR120 (Ichimura,
Nature Epub) collaboration
n~3000 incl. ExomeChip data (currently done in collaboration
with
Wellcome Trust, UK):
- available for own analyses (in
collaboration with WTTC)
Summary
n~5000 data sets from according cohorts
(ongoing)
n~2750 lean, n~1750 obese
(ongoing)
n~2800 incl. consented DNA analysis (ongoing)
n>1800 incl. oGTT's (ongoing)
Setmelanotide Phase 2 Treatment Trial in Patients with Rare Genetic Disorders of Obesity
Besides the common multifactorial and polygenetic causes of obesity, there are also rare cases of single gene mutations interfering with the hypothalamic control of satiety and thus leading to obesity. Those patients are mostly severely affected and present with extreme early-onset obesity and hyperphagia. Setmelanotide, a new drug targeting the MC4-receptor dependent hypothalamic satiety control has shown promising results during the first years of clinical experience. The department of pediatrics at the university hospital in Leipzig is now able to provide treatment with Setmelanotide through an international multicenter clinical trial (NCT0301354) for some of those rare genetic disorders. For more details, please contact us.
Contact details
| Dr. med. Robert Stein |
| Deputy PI |
| Phone.: +49 341 9720296 |
E-Mail: robert.stein@medizin.uni-leipzig.de
